Determining the incidence, risk factors and biological drivers of irritable bowel syndrome (IBS) as part of the constellation of postacute sequelae of SARS-CoV-2 infection (PASC) outcomes in the Arizona CoVHORT-GI: a longitudinal cohort study
Introduction Postacute sequelae of SARS-CoV-2 infection (PASC) are extensive. Also known as long COVID, primary outcomes reported are neurologic, cardiac and respiratory in nature. However, several studies have also reported an increase in gastrointestinal (GI) symptoms and syndromes following COVID...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-01-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/15/1/e095093.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832575479281876992 |
|---|---|
| author | Erika Austhof Kelly M Heslin Xiaoxiao Sun Kristen Pogreba Brown Caitlyn M McFadden Caroline Scranton Ivan Vujkovic-Cviji Dominic Rodriguez Laura Falk Gayatri Arani Victoria Obergh Kate Bessey Kerry Cooper |
| author_facet | Erika Austhof Kelly M Heslin Xiaoxiao Sun Kristen Pogreba Brown Caitlyn M McFadden Caroline Scranton Ivan Vujkovic-Cviji Dominic Rodriguez Laura Falk Gayatri Arani Victoria Obergh Kate Bessey Kerry Cooper |
| author_sort | Erika Austhof |
| collection | DOAJ |
| description | Introduction Postacute sequelae of SARS-CoV-2 infection (PASC) are extensive. Also known as long COVID, primary outcomes reported are neurologic, cardiac and respiratory in nature. However, several studies have also reported an increase in gastrointestinal (GI) symptoms and syndromes following COVID-19. This study of PASC will include extensive analyses of GI symptoms, determine if people with pre-existing irritable bowel syndrome (IBS) are at higher risk of developing PASC generally or PASC-GI, and which biomarkers are impacted and to what degree. This R01 study is being funded by the National Institute of Diabetes and Digestive and Kidney Diseases (1R01DK135483-01) from 2023 to 2028.Methods and analyses This study combines a longitudinal epidemiologic cohort study and in-depth, novel biologic analyses. In collaboration with a pre-existing study, the Arizona CoVID-19 Cohort (CoVHORT)-GI will recruit participants based on the history of COVID infection(s), new or ongoing GI symptoms 3–6 months postinfection, and pre-existing or incident IBS diagnosis to represent five study groups for comparison and analyses. A subset (n=1000) of those recruited will submit both stool and blood samples. Both samples will undergo a novel method to quantitate humoral and mucosal immune responses to host-derived faecal communities in conjunction with magnetic bead-based separation and high-depth shotgun microbial sequencing. Stool samples will also undergo traditional microbiome analyses (diversity and abundance) and faecal calprotectin assays. Additional serum analyses will aim to determine if a proteomics-based signature exists that differentiates a unique biomarker compositional signature discriminating PASC-GI versus no PASC. All laboratory data will be linked with in-depth epidemiologic data on demographics, symptoms and chronic conditions.Ethics and dissemination This study involves human participants and was approved by the University of Arizona Institutional Review Board (IRB (#00002332) and has been deemed minimal risk. Participants gave informed consent to participate in the study before taking part. All publications from the study will be shared back to participants along with alternative lay summaries and webinars to communicate key findings. The data management plan has been published and is publicly available online, including protocols for data requests. |
| format | Article |
| id | doaj-art-c825c334b2d645eba763d1faff051141 |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-c825c334b2d645eba763d1faff0511412025-02-01T06:00:12ZengBMJ Publishing GroupBMJ Open2044-60552025-01-0115110.1136/bmjopen-2024-095093Determining the incidence, risk factors and biological drivers of irritable bowel syndrome (IBS) as part of the constellation of postacute sequelae of SARS-CoV-2 infection (PASC) outcomes in the Arizona CoVHORT-GI: a longitudinal cohort studyErika Austhof0Kelly M Heslin1Xiaoxiao Sun2Kristen Pogreba Brown3Caitlyn M McFadden4Caroline Scranton5Ivan Vujkovic-Cviji6Dominic Rodriguez7Laura Falk8Gayatri Arani9Victoria Obergh10Kate Bessey11Kerry Cooper12Mel and Enid Zuckerman College of Public Health; Department of Epidemiology and Biostatistics, The University of Arizona Health Sciences, Tucson, Arizona, USAMel and Enid Zuckerman College of Public Health; Department of Epidemiology and Biostatistics, The University of Arizona Health Sciences, Tucson, Arizona, USAMel and Enid Zuckerman College of Public Health; Department of Epidemiology and Biostatistics, The University of Arizona Health Sciences, Tucson, Arizona, USAMel and Enid Zuckerman College of Public Health; Department of Epidemiology and Biostatistics, The University of Arizona Health Sciences, Tucson, Arizona, USAMel and Enid Zuckerman College of Public Health; Department of Epidemiology and Biostatistics, The University of Arizona Health Sciences, Tucson, Arizona, USASchool of Animal and Comparative Biomedical Sciences, The University of Arizona College of Agriculture and Life Sciences, Tucson, Arizona, USADepartment of Biomedical Sciences; Research Division of Immunology, Department of Medicine, Karsh Division of Gastroenterology, Cedars-Sinai Medical Center, Los Angeles, California, USASchool of Animal and Comparative Biomedical Sciences, The University of Arizona College of Agriculture and Life Sciences, Tucson, Arizona, USAMel and Enid Zuckerman College of Public Health; Department of Epidemiology and Biostatistics, The University of Arizona Health Sciences, Tucson, Arizona, USAMel and Enid Zuckerman College of Public Health; Department of Epidemiology and Biostatistics, The University of Arizona, Arizona Health Sciences Center, Tucson, Arizona, USASchool of Animal and Comparative Biomedical Sciences, The University of Arizona College of Agriculture and Life Sciences, Tucson, Arizona, USAMel and Enid Zuckerman College of Public Health; Department of Epidemiology and Biostatistics, The University of Arizona Health Sciences, Tucson, Arizona, USASchool of Animal and Comparative Biomedical Sciences, The University of Arizona College of Agriculture and Life Sciences, Tucson, Arizona, USAIntroduction Postacute sequelae of SARS-CoV-2 infection (PASC) are extensive. Also known as long COVID, primary outcomes reported are neurologic, cardiac and respiratory in nature. However, several studies have also reported an increase in gastrointestinal (GI) symptoms and syndromes following COVID-19. This study of PASC will include extensive analyses of GI symptoms, determine if people with pre-existing irritable bowel syndrome (IBS) are at higher risk of developing PASC generally or PASC-GI, and which biomarkers are impacted and to what degree. This R01 study is being funded by the National Institute of Diabetes and Digestive and Kidney Diseases (1R01DK135483-01) from 2023 to 2028.Methods and analyses This study combines a longitudinal epidemiologic cohort study and in-depth, novel biologic analyses. In collaboration with a pre-existing study, the Arizona CoVID-19 Cohort (CoVHORT)-GI will recruit participants based on the history of COVID infection(s), new or ongoing GI symptoms 3–6 months postinfection, and pre-existing or incident IBS diagnosis to represent five study groups for comparison and analyses. A subset (n=1000) of those recruited will submit both stool and blood samples. Both samples will undergo a novel method to quantitate humoral and mucosal immune responses to host-derived faecal communities in conjunction with magnetic bead-based separation and high-depth shotgun microbial sequencing. Stool samples will also undergo traditional microbiome analyses (diversity and abundance) and faecal calprotectin assays. Additional serum analyses will aim to determine if a proteomics-based signature exists that differentiates a unique biomarker compositional signature discriminating PASC-GI versus no PASC. All laboratory data will be linked with in-depth epidemiologic data on demographics, symptoms and chronic conditions.Ethics and dissemination This study involves human participants and was approved by the University of Arizona Institutional Review Board (IRB (#00002332) and has been deemed minimal risk. Participants gave informed consent to participate in the study before taking part. All publications from the study will be shared back to participants along with alternative lay summaries and webinars to communicate key findings. The data management plan has been published and is publicly available online, including protocols for data requests.https://bmjopen.bmj.com/content/15/1/e095093.full |
| spellingShingle | Erika Austhof Kelly M Heslin Xiaoxiao Sun Kristen Pogreba Brown Caitlyn M McFadden Caroline Scranton Ivan Vujkovic-Cviji Dominic Rodriguez Laura Falk Gayatri Arani Victoria Obergh Kate Bessey Kerry Cooper Determining the incidence, risk factors and biological drivers of irritable bowel syndrome (IBS) as part of the constellation of postacute sequelae of SARS-CoV-2 infection (PASC) outcomes in the Arizona CoVHORT-GI: a longitudinal cohort study BMJ Open |
| title | Determining the incidence, risk factors and biological drivers of irritable bowel syndrome (IBS) as part of the constellation of postacute sequelae of SARS-CoV-2 infection (PASC) outcomes in the Arizona CoVHORT-GI: a longitudinal cohort study |
| title_full | Determining the incidence, risk factors and biological drivers of irritable bowel syndrome (IBS) as part of the constellation of postacute sequelae of SARS-CoV-2 infection (PASC) outcomes in the Arizona CoVHORT-GI: a longitudinal cohort study |
| title_fullStr | Determining the incidence, risk factors and biological drivers of irritable bowel syndrome (IBS) as part of the constellation of postacute sequelae of SARS-CoV-2 infection (PASC) outcomes in the Arizona CoVHORT-GI: a longitudinal cohort study |
| title_full_unstemmed | Determining the incidence, risk factors and biological drivers of irritable bowel syndrome (IBS) as part of the constellation of postacute sequelae of SARS-CoV-2 infection (PASC) outcomes in the Arizona CoVHORT-GI: a longitudinal cohort study |
| title_short | Determining the incidence, risk factors and biological drivers of irritable bowel syndrome (IBS) as part of the constellation of postacute sequelae of SARS-CoV-2 infection (PASC) outcomes in the Arizona CoVHORT-GI: a longitudinal cohort study |
| title_sort | determining the incidence risk factors and biological drivers of irritable bowel syndrome ibs as part of the constellation of postacute sequelae of sars cov 2 infection pasc outcomes in the arizona covhort gi a longitudinal cohort study |
| url | https://bmjopen.bmj.com/content/15/1/e095093.full |
| work_keys_str_mv | AT erikaausthof determiningtheincidenceriskfactorsandbiologicaldriversofirritablebowelsyndromeibsaspartoftheconstellationofpostacutesequelaeofsarscov2infectionpascoutcomesinthearizonacovhortgialongitudinalcohortstudy AT kellymheslin determiningtheincidenceriskfactorsandbiologicaldriversofirritablebowelsyndromeibsaspartoftheconstellationofpostacutesequelaeofsarscov2infectionpascoutcomesinthearizonacovhortgialongitudinalcohortstudy AT xiaoxiaosun determiningtheincidenceriskfactorsandbiologicaldriversofirritablebowelsyndromeibsaspartoftheconstellationofpostacutesequelaeofsarscov2infectionpascoutcomesinthearizonacovhortgialongitudinalcohortstudy AT kristenpogrebabrown determiningtheincidenceriskfactorsandbiologicaldriversofirritablebowelsyndromeibsaspartoftheconstellationofpostacutesequelaeofsarscov2infectionpascoutcomesinthearizonacovhortgialongitudinalcohortstudy AT caitlynmmcfadden determiningtheincidenceriskfactorsandbiologicaldriversofirritablebowelsyndromeibsaspartoftheconstellationofpostacutesequelaeofsarscov2infectionpascoutcomesinthearizonacovhortgialongitudinalcohortstudy AT carolinescranton determiningtheincidenceriskfactorsandbiologicaldriversofirritablebowelsyndromeibsaspartoftheconstellationofpostacutesequelaeofsarscov2infectionpascoutcomesinthearizonacovhortgialongitudinalcohortstudy AT ivanvujkoviccviji determiningtheincidenceriskfactorsandbiologicaldriversofirritablebowelsyndromeibsaspartoftheconstellationofpostacutesequelaeofsarscov2infectionpascoutcomesinthearizonacovhortgialongitudinalcohortstudy AT dominicrodriguez determiningtheincidenceriskfactorsandbiologicaldriversofirritablebowelsyndromeibsaspartoftheconstellationofpostacutesequelaeofsarscov2infectionpascoutcomesinthearizonacovhortgialongitudinalcohortstudy AT laurafalk determiningtheincidenceriskfactorsandbiologicaldriversofirritablebowelsyndromeibsaspartoftheconstellationofpostacutesequelaeofsarscov2infectionpascoutcomesinthearizonacovhortgialongitudinalcohortstudy AT gayatriarani determiningtheincidenceriskfactorsandbiologicaldriversofirritablebowelsyndromeibsaspartoftheconstellationofpostacutesequelaeofsarscov2infectionpascoutcomesinthearizonacovhortgialongitudinalcohortstudy AT victoriaobergh determiningtheincidenceriskfactorsandbiologicaldriversofirritablebowelsyndromeibsaspartoftheconstellationofpostacutesequelaeofsarscov2infectionpascoutcomesinthearizonacovhortgialongitudinalcohortstudy AT katebessey determiningtheincidenceriskfactorsandbiologicaldriversofirritablebowelsyndromeibsaspartoftheconstellationofpostacutesequelaeofsarscov2infectionpascoutcomesinthearizonacovhortgialongitudinalcohortstudy AT kerrycooper determiningtheincidenceriskfactorsandbiologicaldriversofirritablebowelsyndromeibsaspartoftheconstellationofpostacutesequelaeofsarscov2infectionpascoutcomesinthearizonacovhortgialongitudinalcohortstudy |